FDA Cmte. To Scrutinize Pulmonary Safety, REMS For Alexza's Inhaled Antipsychotic
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Psychopharmacologic Drugs Advisory Committee will meet Dec. 12 to discuss efficacy and safety of Adasuve, an inhalable version of loxapine, for rapid treatment of agitation in schizophrenic and bipolar patients.
You may also be interested in...
Alexza Expects FDA, EU Regulatory Decisions On Adusave This December
Firm has responded to a second “complete response” letter from FDA and to questions from EU regulators regarding its proposed inhalation formulation of antipsychotic loxapine.
Adasuve’s Extensive REMS Proposal Raises Questions About Whether It Could Work In Practice
Patient screening to ensure pulmonary risks are mitigated could be difficult in emergency room settings, advisory committee says about inhaled loxapine formulation.
Alexza's Inhaled Antipsychotic To Get Indication-Limiting REMS
Firm's proposed risk management plan may exclude patients with COPD or asthma. The application for AZ-004 is expected to be resubmitted by July, with an advisory committee likely by year end.